Appeal No. 2007-0091
Application No. 09/765,491
10. A method to treat the symptoms associated with elevated basic
fibroblast growth factor in a disorder selected from the group consisting of
angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell
carcinoma, malignant melanoma, Kaposi’s sarcoma, psoriasis, and recessive
dystrophic epidermolysis bullosa, comprising administering to the individual
in need of treatment an effective amount of a pharmaceutical composition
comprising a curcuminoid in combination with a pharmaceutically
acceptable carrier to inhibit angiogenesis, wherein the carrier is an ointment
for topical administration containing between one-half percent (0.5%) and
five percent (5%) of the curcuminoid or a polymer formulation for
implantation.
17. A method for inhibiting skin disorders selected from the group
consisting of lymphangiogenesis, Sturge-Weber syndrome, verruca vulgaris,
tuberous sclerosis, venous ulcers, rosacea, eczema, molluscum contagious,
seborrheic keratosis, and actinic keratosis comprising administering to the
individual in need of treatment thereof an angiogenesis inhibitor in an
amount effective to inhibit angiogenesis, wherein the angiogenesis inhibitor
is selected from the group consisting of
tetracyclines inhibiting collagenase, and
a sulfated polysaccharide which inhibits angiogenesis.
Claim 4 is directed to a method for “inhibiting symptoms associated
with angiogenesis” in treating any of several disorders by administering an
angiogenesis inhibitor belonging to one of several classes of compounds.
The claim recites that the angiogenesis inhibitor is administered to an
“individual in need of treatment”; we therefore interpret the claim to require
treatment of an individual suffering from one of the recited disorders. The
claim also states that the angiogenesis inhibitor is administered “in an
amount effective to inhibit angiogenesis.”
Claim 10 is directed to a method of treating any of several skin
disorders (different from the disorders recited in claim 4) by administering
either an ointment containing 0.5% to 5% of a curcuminoid or a
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013